## Contents

### Advances in First-Line Topical Therapies: The Role of a 2-Compound Ointment for Psoriasis Vulgaris

Supported by a restricted educational grant from Warner Chilcott (US), Inc.

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Introduction</td>
<td>Mark G. Lebwohl, MD</td>
</tr>
<tr>
<td>5</td>
<td>Compatibility of Topical Therapies for Psoriasis: Challenges and Innovations</td>
<td>Mark G. Lebwohl, MD, Linda Corvari, PharmD</td>
</tr>
<tr>
<td>11</td>
<td>Using Topical Multimodal Strategies for Patients With Psoriasis</td>
<td>John Y. Koo, MD</td>
</tr>
<tr>
<td>18</td>
<td>The Role of Topical Therapy for Patients With Extensive Psoriasis</td>
<td>Steven R. Feldman, MD, Joel M. Gelfand, MD, Linda Stein Gold, Sherri D. Jones, PharmD</td>
</tr>
<tr>
<td>32</td>
<td>The Roles of Safety and Compliance in Determining Effectiveness of Topical Therapy for Psoriasis</td>
<td>Linda Stein Gold, MD, Linda Corvari, PharmD</td>
</tr>
<tr>
<td>39</td>
<td>An Innovation in Topical Therapy: Insights From International Dermatologists</td>
<td>Knud Kragballe, MD, Linda Corvari, PharmD</td>
</tr>
</tbody>
</table>